Recent Investment Analysts’ Ratings Updates for Glaukos (GKOS)

A number of firms have modified their ratings and price targets on shares of Glaukos (NYSE: GKOS) recently:

• 11/8/2023 – Glaukos was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $83.00 price target on the stock, up previously from $75.00.
• 11/6/2023 – Glaukos was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 11/2/2023 – Glaukos had its price target lowered by analysts at JPMorgan Chase & Co. from $71.00 to $66.00. They now have a “neutral” rating on the stock.
• 11/2/2023 – Glaukos had its price target lowered by analysts at Needham & Company LLC from $89.00 to $83.00. They now have a “buy” rating on the stock.
• 10/29/2023 – Glaukos was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/21/2023 – Glaukos was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 10/13/2023 – Glaukos was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/5/2023 – Glaukos is now covered by analysts at StockNews.com. They set a “hold” rating on the stock.
• 9/27/2023 – Glaukos was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 9/26/2023 – Glaukos had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $90.00 price target on the stock.

Glaukos Stock Up 4.0 %

GKOS stock opened at $66.00 on Wednesday. Glaukos Co. has a 52 week low of $40.45 and a 52 week high of $80.28. The company has a quick ratio of 5.36, a current ratio of 5.95 and a debt-to-equity ratio of 0.74. The firm has a 50-day simple moving average of $70.33 and a 200-day simple moving average of $68.72. The stock has a market capitalization of $3.22 billion, a P/E ratio of -24.54 and a beta of 1.20.

Glaukos (NYSE:GKOS) last posted its quarterly earnings data on Wednesday, November 1st. The medical instruments supplier reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.06. The company had revenue of $78.05 million during the quarter, compared to analyst estimates of $75.25 million. Glaukos had a negative return on equity of 20.82% and a negative net margin of 42.61%. Glaukos’s quarterly revenue was up 9.5% on a year-over-year basis. During the same period in the previous year, the business earned ($0.45) EPS. Equities analysts forecast that Glaukos Co. will post -2.22 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In other news, CEO Thomas William Burns sold 45,000 shares of the firm’s stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $71.98, for a total value of $3,239,100.00. Following the transaction, the chief executive officer now directly owns 54,785 shares of the company’s stock, valued at $3,943,424.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 7.80% of the stock is owned by corporate insiders.

Institutional Trading of Glaukos

Several large investors have recently added to or reduced their stakes in GKOS. Silverarc Capital Management LLC purchased a new stake in Glaukos in the 2nd quarter valued at about $71,000. Tower Research Capital LLC TRC grew its stake in shares of Glaukos by 257.8% in the first quarter. Tower Research Capital LLC TRC now owns 1,238 shares of the medical instruments supplier’s stock valued at $62,000 after buying an additional 892 shares in the last quarter. CWM LLC raised its holdings in shares of Glaukos by 309.5% in the 3rd quarter. CWM LLC now owns 1,384 shares of the medical instruments supplier’s stock valued at $104,000 after buying an additional 1,046 shares during the period. Captrust Financial Advisors lifted its stake in Glaukos by 119.5% during the 1st quarter. Captrust Financial Advisors now owns 1,484 shares of the medical instruments supplier’s stock worth $86,000 after acquiring an additional 808 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC boosted its holdings in Glaukos by 28.5% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,557 shares of the medical instruments supplier’s stock valued at $111,000 after acquiring an additional 345 shares during the period. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.